Hainan Selection Pharmaceutical

Hainan Selection Pharmaceutical is a Chinese pharmaceutical company based in Haikou, Hainan, specializing in the development and manufacturing of chemical drugs and traditional Chinese medicines. Founded in 2001, the company maintains a diverse portfolio of marketed products, including treatments for cardiovascular diseases, neurological disorders, and urological conditions. Key products include Gabapentin, Telmisartan, and the traditional Chinese medicine Qingkailing. The company is closely linked to the SGX-listed STAR Pharmaceutical Limited through shared ownership by Executive Chairman Xu Zhi Bin. Hainan Selection operates GMP-certified facilities and is actively involved in bioequivalence studies for the expansion of its generic drug pipeline.